Oncopeptides AB (publ) (STO:ONCO)

Market Cap	440.23M
Revenue (ttm)	31.65M
Net Income (ttm)	-284.61M
Shares Out	225.76M
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147,422
Average Volume	1,133,748
Open	1.980
Previous Close	1.950
Day's Range	1.950 - 2.030
52-Week Range	1.100 - 5.110
Beta	-0.54
RSI	66.95
Earnings Date	May 15, 2025

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 80
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.